MORPHOLOGIC PATTERN AND PROGNOSTIC SIGNIFICANCE OF CD30 DISTRIBUTION WITHIN NEOPLASTIC CELLS IN HODGKIN LYMPHOMA.
(Abstract release date: 05/19/16)
EHA Library. Gaudio F. 06/09/16; 134760; PB1860
Dr. Francesco Gaudio
Contributions
Contributions
Abstract
Abstract: PB1860
Type: Publication Only
Background
Hodgkin’s lymphoma (HL) is a highly curable disease and 5-year survival is improving, being currently 86%. Cure rates of more than 90% for early HL and more than 70% for those with advanced HL are expected. CD30 protein is expressed on Hodgkin and Reed-Sternberg (HRS) cells in nearly all cases of classical Hodgkin lymphoma (HL). CD30 is present on a cell membrane and on the Golgi complex of the endomembrane cell system. Given the growing clinical application of CD30 targeting we were interested to see if there is variability in distribution of CD30 protein between the cell surface and the cytoplasm and the impact on outcome.
Aims
Given the growing clinical application of CD30 targeting we were interested to see if there is variability in distribution of CD30 protein between the cell surface and the cytoplasm and the impact on outcome.
Methods
To further assess the presenting features and the prognostic significance of CD30 expression in HL we performed a retrospective single institution study of 179 cases with a median follow-up of 5 years. The median ages were 40 years (range, 14–83 years) for men and 34 years (range, 16–77 years) for women; Histological subtypes of HL were nodular sclerosis in 155 (87%), mixed cellularity in 19 (11%), lymphocyte rich in 5 (3%) of cases. Stages III-IV were present in 116 pts (65%), bulky disease in 68 pts (38%), extranodal disease in 21 (12%) and 73 (41%) had a score >2 (intermediate-high-risk). Combined radio-chemotherapy was administered in 116 pts (65%) and chemotherapy alone in 63 (35%).The CD30 protein was evaluated in formalin-fixed paraffinembedded (FFPE) tissue sections by immunohistochemistry (IHC) with monoclonal mouse antihuman antibody CD30 (clone Ber-H2) (Dako). Morphological pattern (localization of CD30) of CD30 expression was evaluated in each case under a microscope examination.
Results
FFPE tissue specimens from 179 HL patients were examined. Immunophenotype was typical of classical HL, and HRS cells were positive for CD30 in all cases. Immunostaining for CD30 was present only on the Golgi body in 147 (82%) of cases, and it was demonstrated on the Golgi body and on the cell membrane in 32 (18%) of cases. The 32 patients with golgi and surface CD30 expression had poor prognosis compared with the patients with CD30 surface alone (5 year progression-free survival [PFS], 20% versus 86%; p<0.001).
Conclusion
In our series of 179 patients with classical HL, predominant pattern of CD30 expression was cytoplasmic (Golgi body), and only 18% of cases demonstrated cell surface and cytoplasmic expression, with the evidence of poor prognosis.
Session topic: E-poster
Type: Publication Only
Background
Hodgkin’s lymphoma (HL) is a highly curable disease and 5-year survival is improving, being currently 86%. Cure rates of more than 90% for early HL and more than 70% for those with advanced HL are expected. CD30 protein is expressed on Hodgkin and Reed-Sternberg (HRS) cells in nearly all cases of classical Hodgkin lymphoma (HL). CD30 is present on a cell membrane and on the Golgi complex of the endomembrane cell system. Given the growing clinical application of CD30 targeting we were interested to see if there is variability in distribution of CD30 protein between the cell surface and the cytoplasm and the impact on outcome.
Aims
Given the growing clinical application of CD30 targeting we were interested to see if there is variability in distribution of CD30 protein between the cell surface and the cytoplasm and the impact on outcome.
Methods
To further assess the presenting features and the prognostic significance of CD30 expression in HL we performed a retrospective single institution study of 179 cases with a median follow-up of 5 years. The median ages were 40 years (range, 14–83 years) for men and 34 years (range, 16–77 years) for women; Histological subtypes of HL were nodular sclerosis in 155 (87%), mixed cellularity in 19 (11%), lymphocyte rich in 5 (3%) of cases. Stages III-IV were present in 116 pts (65%), bulky disease in 68 pts (38%), extranodal disease in 21 (12%) and 73 (41%) had a score >2 (intermediate-high-risk). Combined radio-chemotherapy was administered in 116 pts (65%) and chemotherapy alone in 63 (35%).The CD30 protein was evaluated in formalin-fixed paraffinembedded (FFPE) tissue sections by immunohistochemistry (IHC) with monoclonal mouse antihuman antibody CD30 (clone Ber-H2) (Dako). Morphological pattern (localization of CD30) of CD30 expression was evaluated in each case under a microscope examination.
Results
FFPE tissue specimens from 179 HL patients were examined. Immunophenotype was typical of classical HL, and HRS cells were positive for CD30 in all cases. Immunostaining for CD30 was present only on the Golgi body in 147 (82%) of cases, and it was demonstrated on the Golgi body and on the cell membrane in 32 (18%) of cases. The 32 patients with golgi and surface CD30 expression had poor prognosis compared with the patients with CD30 surface alone (5 year progression-free survival [PFS], 20% versus 86%; p<0.001).
Conclusion
In our series of 179 patients with classical HL, predominant pattern of CD30 expression was cytoplasmic (Golgi body), and only 18% of cases demonstrated cell surface and cytoplasmic expression, with the evidence of poor prognosis.
Session topic: E-poster
Abstract: PB1860
Type: Publication Only
Background
Hodgkin’s lymphoma (HL) is a highly curable disease and 5-year survival is improving, being currently 86%. Cure rates of more than 90% for early HL and more than 70% for those with advanced HL are expected. CD30 protein is expressed on Hodgkin and Reed-Sternberg (HRS) cells in nearly all cases of classical Hodgkin lymphoma (HL). CD30 is present on a cell membrane and on the Golgi complex of the endomembrane cell system. Given the growing clinical application of CD30 targeting we were interested to see if there is variability in distribution of CD30 protein between the cell surface and the cytoplasm and the impact on outcome.
Aims
Given the growing clinical application of CD30 targeting we were interested to see if there is variability in distribution of CD30 protein between the cell surface and the cytoplasm and the impact on outcome.
Methods
To further assess the presenting features and the prognostic significance of CD30 expression in HL we performed a retrospective single institution study of 179 cases with a median follow-up of 5 years. The median ages were 40 years (range, 14–83 years) for men and 34 years (range, 16–77 years) for women; Histological subtypes of HL were nodular sclerosis in 155 (87%), mixed cellularity in 19 (11%), lymphocyte rich in 5 (3%) of cases. Stages III-IV were present in 116 pts (65%), bulky disease in 68 pts (38%), extranodal disease in 21 (12%) and 73 (41%) had a score >2 (intermediate-high-risk). Combined radio-chemotherapy was administered in 116 pts (65%) and chemotherapy alone in 63 (35%).The CD30 protein was evaluated in formalin-fixed paraffinembedded (FFPE) tissue sections by immunohistochemistry (IHC) with monoclonal mouse antihuman antibody CD30 (clone Ber-H2) (Dako). Morphological pattern (localization of CD30) of CD30 expression was evaluated in each case under a microscope examination.
Results
FFPE tissue specimens from 179 HL patients were examined. Immunophenotype was typical of classical HL, and HRS cells were positive for CD30 in all cases. Immunostaining for CD30 was present only on the Golgi body in 147 (82%) of cases, and it was demonstrated on the Golgi body and on the cell membrane in 32 (18%) of cases. The 32 patients with golgi and surface CD30 expression had poor prognosis compared with the patients with CD30 surface alone (5 year progression-free survival [PFS], 20% versus 86%; p<0.001).
Conclusion
In our series of 179 patients with classical HL, predominant pattern of CD30 expression was cytoplasmic (Golgi body), and only 18% of cases demonstrated cell surface and cytoplasmic expression, with the evidence of poor prognosis.
Session topic: E-poster
Type: Publication Only
Background
Hodgkin’s lymphoma (HL) is a highly curable disease and 5-year survival is improving, being currently 86%. Cure rates of more than 90% for early HL and more than 70% for those with advanced HL are expected. CD30 protein is expressed on Hodgkin and Reed-Sternberg (HRS) cells in nearly all cases of classical Hodgkin lymphoma (HL). CD30 is present on a cell membrane and on the Golgi complex of the endomembrane cell system. Given the growing clinical application of CD30 targeting we were interested to see if there is variability in distribution of CD30 protein between the cell surface and the cytoplasm and the impact on outcome.
Aims
Given the growing clinical application of CD30 targeting we were interested to see if there is variability in distribution of CD30 protein between the cell surface and the cytoplasm and the impact on outcome.
Methods
To further assess the presenting features and the prognostic significance of CD30 expression in HL we performed a retrospective single institution study of 179 cases with a median follow-up of 5 years. The median ages were 40 years (range, 14–83 years) for men and 34 years (range, 16–77 years) for women; Histological subtypes of HL were nodular sclerosis in 155 (87%), mixed cellularity in 19 (11%), lymphocyte rich in 5 (3%) of cases. Stages III-IV were present in 116 pts (65%), bulky disease in 68 pts (38%), extranodal disease in 21 (12%) and 73 (41%) had a score >2 (intermediate-high-risk). Combined radio-chemotherapy was administered in 116 pts (65%) and chemotherapy alone in 63 (35%).The CD30 protein was evaluated in formalin-fixed paraffinembedded (FFPE) tissue sections by immunohistochemistry (IHC) with monoclonal mouse antihuman antibody CD30 (clone Ber-H2) (Dako). Morphological pattern (localization of CD30) of CD30 expression was evaluated in each case under a microscope examination.
Results
FFPE tissue specimens from 179 HL patients were examined. Immunophenotype was typical of classical HL, and HRS cells were positive for CD30 in all cases. Immunostaining for CD30 was present only on the Golgi body in 147 (82%) of cases, and it was demonstrated on the Golgi body and on the cell membrane in 32 (18%) of cases. The 32 patients with golgi and surface CD30 expression had poor prognosis compared with the patients with CD30 surface alone (5 year progression-free survival [PFS], 20% versus 86%; p<0.001).
Conclusion
In our series of 179 patients with classical HL, predominant pattern of CD30 expression was cytoplasmic (Golgi body), and only 18% of cases demonstrated cell surface and cytoplasmic expression, with the evidence of poor prognosis.
Session topic: E-poster
{{ help_message }}
{{filter}}